The health system’s clinicians specializing in brain tumors will use Neosoma’s technology and provide feedback to the company. Additional parts of the collaboration include data-sharing, clinical research and strategic investment from Hackensack, according to a Feb. 24 Neosoma news release.
Neosoma recently received FDA clearance for its AI-based neuro-health software device, Neosoma HGG.
“Neosoma helps to avoid interruptions in care, unnecessary surgeries, and unnecessary changes in therapy,” Joseph Landolfi, DO, a neuro-oncologist and the chief medical officer at the system’s Edison, N.J.-based JFK University Medical Center, said in the release. “The entire team benefits from centralized information, more efficient communication, and treatment protocols tailored to each specific patient.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.